Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 9 518 / https://doi.org/10.3332/ecancer.2015.518

Conference Report

Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer

The refinement of the classification, the risk of relapse and the prediction of response to multidisciplinary treatment for early breast cancer has been the major theme of the 14th St Gallen International Breast Cancer Consensus Conference 2015. The meeting, held in Vienna, assembled 3500–4000 participants from 134 countries worldwide. It culminated, on the final day, with the International Consensus Session, delivered by 40–50 of the world’s most experienced opinion leaders in the field of breast cancer treatment. The panelists addressed the “semantic” classification of breast cancer subtypes by pathology-based biomarkers (e.g. estrogen receptor, progesterone receptor and HER2) vs genomic classifiers. They also refined the biomarker prognostication dissecting the impact of the various gene signatures and pathologic variables in predicting the outcome of patients with early breast cancer in terms of early and late relapse. Finally they addressed the challenges stemming from the intra- and inter-observer variability in the assessment of pathologic variables and the role of gene signatures for the prediction of response to specific therapeutic approach such as endocrine therapy and chemotherapy and for personalizing local treatment of patients with early breast cancer. The vast majority of the questions asked during the  onsensus were about controversial issues. The opinion of the panel members has been used to implement guidance for treatment choice. This is the unique feature of the St. Gallen Consensus, ensuring that the resulting recommendations will take due cognizance of the variable resource limitations in different countries. Information derived from evidence based medicine and large meta-analyses is of obvious and enormous value. The weakness of this approach is that it gives particular weight to older trials (which have accumulated more event endpoints) and is frequently unable to collect sufficient detail on the patients and tumors in the trials to allow assessment of whether the treatments which are better on average offer equal value to all currently definable patient subgroups. What St Gallen can provide is clinically useful updated breast cancer treatment consensus for the majority of patients treated outside of clinical trials (>90%) in most countries.

Keywords: 14th St Gallen Consensus Conference 2015, Early Breast Cancer

Loading Article Metrics ... Please wait

Related articles

Research: Health-related quality of life before and during chemotherapy in patients with early-stage breast cancer

Abstract | Full Article | PDF Published: 27 Jan 2020 / https://doi.org/10.3332/ecancer.2020.1007

Case Report: Eribulin-induced radiation recall dermatitis: a case report and brief review of the literature

Abstract | Full Article | PDF Published: 23 Jan 2020 / https://doi.org/10.3332/ecancer.2020.1006

Short Communication: Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution

Abstract | Full Article | PDF Published: 23 Jan 2020 / https://doi.org/10.3332/ecancer.2020.1005

Research: Socio-culturally mediated factors and lower level of education are the main influencers of functional cervical cancer literacy among women in Mayuge, Eastern Uganda

Abstract | Full Article | PDF Published: 21 Jan 2020 / https://doi.org/10.3332/ecancer.2020.1004

Research: High depletion of breast cancer cells from the peripheral blood with the method of non-specific separation

Abstract | Full Article | PDF Published: 21 Jan 2020 / https://doi.org/10.3332/ecancer.2020.1003



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation